Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
SepsisCandida
Interventions
DRUG

Amphotericine in liposome (Ambisome®)

2 IV infusions separated by one week 10 mg/kg per injection

Trial Locations (2)

38000

RECRUITING

Chu Michallon, Grenoble

75010

NOT_YET_RECRUITING

Hopital Saint Louis, Paris

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Fovea

OTHER

NCT00697944 - Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients | Biotech Hunter | Biotech Hunter